Objective: Previous gene expression analysis identified a network of coexpressed genes that is associated with bamyloid neuropathology and cognitive decline in older adults. The current work targeted influential genes in this network with quantitative proteomics to identify potential novel therapeutic targets. Methods: Data came from 834 community-based older persons who were followed annually, died, and underwent brain autopsy. Uniform structured postmortem evaluations assessed the burden of b-amyloid and other common age-related neuropathologies. Selected reaction monitoring quantified cortical protein abundance of 12 genes prioritized from a molecular network of aging human brain that is implicated in Alzheimer's dementia. Regression and linear mixed models examined the protein associations with b-amyloid load and other neuropathological indices as well as cognitive decline over multiple years preceding death. Results: Average age at death was 88.6 years. Overall, 349 participants (41.9%) had Alzheimer's dementia at death. A higher level of PLXNB1 abundance was associated with more b-amyloid load (p 5 1.0 3 10 27 ) and higher PHFtau tangle density (p 5 2.3 3 10 27 ), and the association of PLXNB1 with cognitive decline is mediated by these known Alzheimer's disease pathologies. On the other hand, higher IGFBP5, HSPB2, and AK4 and lower ITPK1 levels were associated with faster cognitive decline, and, unlike PLXNB1, these associations were not fully explained by common neuropathological indices, suggesting novel mechanisms leading to cognitive decline. Interpretation: Using targeted proteomics, this work identified cortical proteins involved in Alzheimer's dementia and begins to dissect two different molecular pathways: one affecting b-amyloid deposition and another affecting resilience without a known pathological footprint.
and the burden of brain b-amyloid deposition, the pathological hallmark of Alzheimer's disease (AD), as well as decline in cognition, the clinical hallmark of Alzheimer's dementia. 3 This group of coexpressed genes, arbitrarily labeled module 109 (m109), represents a cortical transcriptional program that is the most proximal molecular event occurring before cognitive decline in aging. Furthermore, our previous modeling suggests that m109 is causally implicated in Alzheimer's dementia through two independent mechanisms: a minor effect on brain-amyloid deposition and a major effect that is independent of b-amyloid and other pathologies. 3 The m109 consists of 390 genes, and we prioritized 30 unique nodal genes as potential drivers of the network's biological function. In an initial round of functional validation, we tested 21 of these 30 genes in human astrocytes and/or human neurons derived from induced pluripotent stem cell. Of the 14 genes examined in vitro using primary human astrocytic cell cultures, INPPL1 and PLXNB1 RNA knockdown reproducibly reduced the production of pathogenic soluble Ab42. Interestingly, none of the genes were validated following neuronal perturbation. These experiments provided functional validation that INPPL1 and PLXNB1 genes may play an important role in mediating m109's effect on bamyloid metabolism. Much of the variance in cognitive decline explained by m109 remains unexplained after we account for the effect of PLXNB1 and INPPL1, supporting the network finding that some genes in this network influence cognitive decline independent of AD pathology. 3 In this study, we used selection reaction monitoring (SRM) quantitative proteomics to quantify protein levels of 12 of the nodal genes within m109 ( Fig  F1  1) . With these data, we extended our previous findings in two ways. First, we quantified the protein abundance of PLXNB1, our best candidate gene (INPPL1 did not pass quality control), in postmortem human brain, confirmed its relation to b-amyloid at the protein level, and examined its association with other Alzheimer's pathological and clinical phenotypes. Second, we quantified 11 additional proteins prioritized within m109 (some of which could not be tested in our in vitro system) to examine their associations with cognitive decline as well as AD and other age-related neuropathologies.
Patients and Methods

Study Participants
Participants were community-based older persons enrolled in two ongoing cohort studies of aging and dementia, the ROS (Religious Orders Study) 4 and MAP (Rush Memory and Aging Project). 5 Both studies were approved by the Institutional Review Board of Rush University Medical Center (Chicago, IL). Participants entered the studies without known dementia and agreed to annual assessments as well as brain donation after death. A written informed consent and an anatomical gift act were obtained from each participant. SRM proteomics was performed at Pacific North National Laboratory (PNNL). Brain samples for distribution to PNNL were identified on November 16, 2012. At that time, there were 995 participants who had died and had completed cognitive assessments and neuropathological evaluation. By mid-January 2016, we had sent the first 834 samples in the interest of time elected to perform the first round of SRM proteomics that included the proteins from m109. Average age at death was 88.6 years (standard deviation [SD], 6.5; range, 65.9-108.3). A majority were female (65.8%) and almost all were non-Latino whites (95.9%). The average years of education was 16.3 (SD, 3.6; range, .
Cognitive Assessment and Clinical Diagnosis
Detailed neuropsychological and clinical examinations were administered each year to participants in both studies. 6 Overall follow-up rate exceeded 95%. The cognitive battery consists of 17 tests and assesses multiple domains of cognitive ability. To minimize floor or ceiling artifact of individual test, a composite score was used to measure the decline in cognition many years preceding death. Briefly, scores for each test were standardized using baseline means and SDs of both cohorts, and the resulting z-scores were then averaged across the tests to derive the measure of global cognition. Annual clinical diagnosis was based on the recommendations of the joint working group of the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. 7 Results from cognitive assessment and physical examination were reviewed, and a diagnosis of Alzheimer's dementia was made by a clinician if participant demonstrated progressive worsening of cognition as well as deficit in memory and at least one other cognitive domain. 8 At time of death, a summary diagnostic opinion regarding the participant's final cognitive status was provided by a neurologist after reviewing available clinical data. 9 
Neuropathology Measures
Brain autopsy follows standard protocol. 10 Neuropathological evaluations, blinded to clinical data, assessed the burden of common age-related neuropathologies, including AD, cerebral infarcts, Lewy bodies, hippocampal sclerosis, transactive response DNA-binding protein 43 kDa (TDP-43), cerebral amyloid angiopathy (CAA), atherosclerosis, and arteriolosclerosis. Specifically, b-amyloid and PHFtau tangle pathologies were measured in 8 predetermined brain regions using molecular specific immunohistochemistry 11 . 20 mm sections were immunostained with one of three monoclonal antibodies (4G8, 1:9,000, Covance Labs, Madison, WI; 6F/3D, 1:50, Dako North America Inc., Carpinteria, CA; and 10D5, 1:600, Elan Pharmaceuticals, San Francisco, CA) for b-amyloid. Paired helical filament tau (PHFtau) tangles were assessed using an antibody specific for phosphorylated tau: AT8 (1:1,000; Innogenetics, San Ramon, CA). b-amyloid deposition was quantified using image analysis. Percent area positive for bamyloid within each region was square-root transformed and averaged to compute a summary score for b-amyloid load. PHFtau tangles per mm 2 were quantified using stereology within each region and then averaged to obtain a summary score for PHTtau tangle density. Chronic macroscopic infarcts were recorded during gross examination and confirmed histologically. 12 Presence of microinfarcts were determined in a minimum of nine regions, identified using hematoxylin and eosin (H&E) stain. 13 Lewy bodies in substantial nigra and limbic and neocortical regions was identified using a-synuclein immunostaining. 14 Hippocampal sclerosis was assessed using H&E-stained sections from midhippocampus. 15 TDP-43 staging from amygdala to limbic and neocortical regions were determined using monoclonal TDP-43 antibody. 16 CAA was assessed in four neocortical regions using immunohistochemistry. 17 b-amyloid depositions in meningeal and parenchymal vessels in each region were rated and averaged across to obtain a summary CAA measure. Severity of atherosclerosis was graded by gross examination of vessels in the circle of Willis, and arteriolosclerosis was graded on H&E-stained sections of basal ganglia. 18 
Targeted SRM Proteomics
Targeted proteomics analysis was performed using frozen tissue from dorsolateral prefrontal cortex (DLPFC), the same brain region selected for RNAseq and other omic analysis. The sample preparation for LC-SRM analysis follows the standard protocol. 19, 20 To meet the scale of the study, all the liquid handling steps were performed in 96-well plate format using Epmotion 5075 TMX (Eppendorf ) or Liquidator96 (Rainin Table 1 ). For the previously prioritized 30 genes, we selected 55 proteotypic peptides based on reanalysis of a comprehensive liquid chromatography (LC) with tandem mass spectrometry data set of all human tissues. 21 The 55 synthetic heavy peptides labeled with 13 C/ 15 N on C-terminal lysine or arginine were purchased from New England Peptide (Gardner, MA) with cysteine modification with carbamidomethylation. Twenty-seven of the 55 peptides were detected in a few representative brain samples (Supplementary Table 1 , column 4), which were subsequently quantified in the entire sample set with 79 technical controls. Details on SRM method configuration are reported in Supplementary Table 2 . LC-SRM experiments were performed on a nano ACQ-UITY UPLC coupled to a TSQ Vantage MS instrument, with 2 ml of sample injection for each measurement. Formic acid (0.1%) in water and 0.1% in 90% acetonitrile were used as buffer A and B, respectively. Peptide separations were performed by an ACQUITY UPLC BEH 1.7-mm C18 column (75 mm i.d. 3 25cm) at a flow rate 350nl/min using gradient of 0.5% of buffer B in 0 to 14.5 minutes, 0.5% to 15% B in 14.5 to 15.0 minutes, 15% to 40% B in 15 to 30 minutes, and 45% to 90% B in 30 to 32 minutes. Heated capillary temperature and spray voltage were set at 350 8C and 2.4kV, respectively. Both Q1 and Q3 were set as 0.7 full width at half maximum. Scan width of 0.002m/z and a dwell time of 10ms were used. SRM data were analyzed by Skyline software (Skyline Software Systems, Inc., Herndon, VA). 22 All the data were manually inspected to ensure that (1) chromatographic peaks of the endogenous peptides coincide with the standards; (2) shapes of the peaks agree; and (3) orders and ratios of the transition intensities agree between light and heavy isotopes. Transitions interfering with coeluting peptides were excluded from quantification. Examples of chromatograms from randomly selected samples are shown at https://www.radc.rush.edu/targeted_srm. htm. Peak area ratios of endogenous light peptides and their heavy isotope-labeled internal standards (ie, L/H peak area ratios) were then automatically calculated by the Skyline software, and the transitions without matrix interference were used for accurate quantification. Reproducibility of measurements and quality of peptide quantification were assessed using 79 technical controls. Technical controls came from a pooled sample by mixing an aliquot of each homogenized brain sample. These identical samples were randomly scattered across the plates with a ratio of 8 per plate. Notably, variance across technical controls is exclusively attributed to sample processing and instrumental measurements. We consider a peptide signal informative if the variance across the individual brain samples, which includes both technical and biological variances, exceeds 2-fold of technical variance. Nine of 27 detectable peptides did not meet the 2-fold threshold and were excluded (Supplementary Table 1 , column 5). Two peptides (BCL2L1_1 and SLC6A12_1) had the ratios close to 2, but were retained considering reasonably low coefficient of variation values and convincing chromatographic profiles.
After testing for sensitivity and quality of quantification, we retained 18 peptides corresponding to 12 proteins, including AK4, ANKRD40, BCL2L1, FBXO2, HSPB2, IGFBP5, ITPK1, KIF5B, PLXNB1, SASH1, SLC6A12, and VAT1 (Supplementary Table 3 ). For proteins with multiple peptides quantified, the peptide with the highest signal-to-noise ratio was used. The peptide relative abundances were log2 transformed and centered at the median.
Statistical Analysis
Spearman correlations, t tests, or analysis of variance described bivariate relationships between demographic, cognitive, and neuropathological measures with targeted protein abundance. Because the in vitro model reported that knockdown of PLXNB1 gene expression reduces b-amyloid, we tested the hypothesis that higher PLXNB1 protein abundance was associated with more-severe b-amyloid. To do so, we fit linear regression models with b-amyloid load as the continuous outcome and PLXNB1 abundance as the predictor. We subsequently examined the protein association with other pathological and cognitive phenotypes.
To follow up on the effect of m109 overexpression on cognitive decline, we also examined 11 additional prioritized proteins in relation to cognitive decline in a series of linear mixed models. In these models, annual global cognitive scores was the longitudinal continuous outcome; the model predictors included a term for time in years preceding death that estimates mean rate of cognitive decline (ie, slope) and a term for the interaction between time and protein abundance that estimates mean change of cognitive slope with every log2 unit increase in protein abundance. For proteins shown to have an association with cognitive decline, we further examined their relationships with common age-related neuropathologies. Here, each neuropathologic index was the outcome, and linear regression or logistic regression models were used for hypothesis testing.
Analyses were performed using SAS/STAT software (SAS Institute Inc., Cary, NC). Unless otherwise noted, all models were controlled for demographics and the technical confounder of plate.
Results
Characteristics of Study Participants
At time of death, 349 people (41.9%) were diagnosed with Alzheimer's dementia. Percentage was higher for pathological diagnosis of AD, where 520 (62.4%) met intermediate or high likelihood for AD according to modified NIA-Reagan criteria. 23 In addition, a considerable burden of non-AD pathologies was observed (Table   ANNALS of Neurology T1  1) . Notably, over 50% of these decedents had TDP-43 inclusions, 20% had Lewy bodies, and nearly 10% had hippocampal sclerosis. Cerebral vascular diseases were also common. Over one third had macroscopic infarcts, and nearly 30% had microinfarcts. Moderate-to-severe atherosclerosis and arteriolosclerosis were observed in around 40% each, as was moderate-to-severe CAA.
Overall, we did not observe strong correlations between protein abundance and demographics, with the exception for VAT1, where males had higher VAT1 protein level than females. As expected, PLXNB1 was strongly correlated with b-amyloid and PHFtau tangles. Several proteins, including AK4, FBXO2, HSPB2, IGFBP5, ITPK1, and VAT1, also showed bivariate correlations with AD pathologies. In addition, we observed that ITPK1 protein level was lower with more-advanced staging of TDP-43 inclusions, and IGFBP5 protein level was elevated with the presence of Lewy bodies. There was a lack of correlation between targeted proteins and cerebral infarcts or vessel pathologies.
PLXNB1 and b-Amyloid Pathology
We first tested the association of PLXNB1 protein abundance with b-amyloid load. Consistent with the finding from our previous in vitro models, higher PLXNB1 abundance was associated with more b-amyloid load Because the bivariate examination suggests that PLXNB1 protein level was primarily correlated with AD pathology, we next tested the hypothesis that the association of PLXNB1 with cognitive decline was attenuated after accounting for AD pathology. In a linear mixed model adjusted for age, sex, education, and plate, PLXNB1 abundance in the DLPFC was associated with faster cognitive decline (estimate 5 20.044; SE 5 0.013; p 5 0.001). Next, we augmented the model by further adjusting for b-amyloid load and PHFtau tangle density. Both b-amyloid (estimate 5 20.010; SE 5 0.004; p 5 0.008) and tangles (estimate 5 20.045; SE 5 0.003; p < 0.001) were strongly related to faster decline. By contrast, the association of PLXNB1 was attenuated and no longer significant (p 5 0.645), suggesting that its role in aging-related cognitive decline is mediated by AD pathology ( Fig  F2  2) . 
ANNALS of Neurology
Associations of IGFBP5, HSPB2, AK4, and ITPK1 With Cognitive Decline and Neuropathologies
We examined the other 11 targeted proteins from m109 in relation to cognitive decline. Considering that multiple proteins were tested separately, statistical significance was adjusted using Bonferroni correction at a level of 0.005 (0.05/11), although this is overly conservative given that all of these genes are derived from a single network module composed of coexpressed genes. Four proteins survived full correction for multiple testing (Table  T2 2). IGFBP5 had the strongest signal: Higher IGFBP5 abundance was associated with a faster rate of cognitive decline (p 5 1.2 3 10 216 ).
Both AK4 and HSPB2 showed similar associations with faster cognitive decline. The ITPK1 protein was also associated with decline, but the direction was reversed such that higher abundance was associated with less decline (p 5 7.8 3 10
25
). We next investigated the associations of these four proteins with AD and other common pathologies ( Fig  F3  3) , and the results revealed distinct association patterns. IGFBP5 and HSPB2 were implicated in both AD and other neuropathologies. After correcting for multiple testing to account for the 10 different neuropathological indices being evaluated, higher IGFBP5 protein level was associated with more b-amyloid and PHFtau tangles, as well as greater odds for Lewy bodies and more-severe TDP-43 pathologies (ps < 0.005). Notably, the effect of the protein on cognitive decline was not fully explained by these pathologies. Analysis using a linear mixed model showed that the association of IGFBP5 with cognitive decline was attenuated, but remained significant, after the adjustment for AD, Lewy body, and TDP-43 pathologies (p 5 1.7 3 10
27
). Figure  F4  4A illustrates that the correlation between IGFBP5 and rate of cognitive decline after adjusting for neuropathologies (gray line) was weaker than the one before the adjustment (black line), but it still evidently deviated from the null. This suggests that IGFBP5 may also be mediating the effects of other, as yet unmeasured neuropathologies. Similarly, higher HSPB2 protein level was associated with more PHFtau tangles and more-severe CAA, and the association of HSPB2 with cognitive decline was attenuated, but persisted after adjusting for tangles and CAA (p 5 0.020; Fig 4B) . Unfortunately, the IGFBP5 and HSPB2 genes were not included in our previous in vitro models in neurons or astrocytes, so we have no parallel in vitro data.
By contrast, both AK4 and ITPK1 were associated with cognitive decline (Fig  F5  5) , and the two proteins had little relationship with the brain pathologies measured in this study. None of the associations of AK4 with Black line represents the regression line between protein abundance and cognitive decline without controlling for neuropathologies. White circles are person-specific rates of decline estimated from a separate linear mixed model adjusted for demographics and neuropathologies, plotted against protein abundance. Gray line represents the regression line between protein abundance and cognitive decline after controlling for neuropathologies. Notably, the gray line is flatter than the black line, but it still deviates from the horizontal reference line that represents the null.
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Volume 84, No. 1 neuropathology measures survived the correction for multiple testing, suggesting that these pathologies were not primary drivers for the effect of AK4 on cognitive decline. We did not observe an ITPK1 association with b-amyloid load. Higher ITPK1 abundance was associated with lower PHFtau tangle density, but the association of ITPK1 with cognitive decline persisted after the adjustment for the tangle pathology (p 5 0.002). In our previous in vitro models, knockdown of ITPK1 did not significantly alter Ab42 secretion in neurons or astrocytes, consistent with our current findings of no relation to b-amyloid (AK4 was not tested). Finally, we examined the extent to which protein levels of IGFBP5, HSPB2, AK4, and ITPK1 explain the variance in person-specific cognitive decline, above and beyond the effect by common neuropathologies. Consistent with our previous report, AD, cerebral infarcts, Lewy bodies, hippocampal sclerosis, TDP-43, CAA, atherosclerosis, and arteriolosclerosis explained 38% of variance in cognitive decline. After adjusting for these neuropathologies, IGFBP5 protein levels explained an additional 3%, HSPB2 0.4%, AK4 1%, and ITPK1 1%, each separately. Together, they explained a total of 4% of variance in cognitive decline, an important fraction for which we now have biological correlates to explore further.
Discussion
Using a systems biology approach, we previously reported that overexpression of an RNA coexpression network module, m109, results in more b-amyloid pathology and faster cognitive decline. Our initial in vitro validation effort implicated two of these genes-INPPL1 and PLXNB1-in b-amyloid pathology. PLXNB1 was further validated in this work, with a consistent direction of effect. All three sets of data-cortical RNA sequence data, in vitro perturbation data from human astrocytes, and now direct measure of cortical protein abundanceconverge in supporting a role for PLXNB1 in AD pathology. Cross-sectional RNAseq and proteomic measures yield associations, preventing a formal comment on causality; however, the in vitro experiment suggests that one effect of PLXNB1 could be causal in astrocytes. That is, increasing levels of PLXNB1 may contribute to accumulation of b-amyloid and is less likely to be a result of that pathology. PLXNB1 is the transmembrane receptor for Semaphorin 4D (SEMA4D). The protein functions as a GTPase activating protein for R-Ras, which downregulates R-Ras activity in response to SEMA4D and induces axonal growth cone collapse. 24, 25 However, little has been reported about the role of PLXNB1 in Alzheimer's dementia. Data in this study add an important second layer of validation to our efforts to dissect cortical molecular networks to identify new targets for Alzheimer's dementia intervention. In particular, we find that level of protein expression is related to AD in the target human organ, providing a robust set of observations for further drug development studies. Unfortunatley, the other lead m109 candidate gene, INPPL1, was not evaluated in this effort because the SRM assay failed quality-control measures. It is currently being repeated.
PLXNB1 confirms our network approach and provides a new target in relation to the biology of bamyloid. However, it does not fully explain the role of m109 in cognitive decline. The other genes prioritized from m109 offer an exciting, complementary set of insights into the role of the module: AD and other pathologies do not fully explain either the association of higher levels of IGFBP5, HSPB2, and AK4 with faster cognitive decline or the association of higher ITPK1 with slower decline. IGFBP5 shows the strongest signal for cognitive decline, and it is also associated with a broader range of neuropathologies. The burden of these pathologies only partially mediates the effect of this protein on cognitive decline. IGFBP5 is a binding protein that regulates the activity of insulin-like growth factors (IGFs), which play a crucial role in neurodevelopment 26 and apoptosis. 27 Evidence from mice models show that neuronal IGFBP5 overexpression results in motor neuron degeneration and myelination defects. 28 HSPB2 belongs to a superfamily of heat shock proteins (HSPs) that regulate protein aggregation and clearance as well as respond to proteotoxic stress. 29 An earlier study on postmortem human brain reported extracellular expression of HSPB2 in plaques and CAA, suggesting the protein's involvement in fibrillar b-amyloid deposition. 30 In this study, we also observed a strong relationship between HSPB2 and CAA, and the protein association with b-amyloid is nominal; however, these associations do not fully explain HSPB2's role in cognitive decline. The last two proteins, AK4 and ITPK1, are of particular interest given that both are associated with cognitive decline, but have little relation to brain pathologies measured in this study. They can be considered as proteins associated with resilience. Here, we define resilience as changes in cognitive function that are not explained by known neuropathologies (ie, residual cognitive decline). 31 This definition assumes that all living humans have some resilience, with some having more and others less than average. Thus, resilience factors may be associated with slower or faster decline as we have shown previously. 32 AK4 is a mitochondrial protein that belongs to an adenylate kinase (AK) family of enzymes. Human AK4 is reported to phosphorylate AMP, dAMP, CMP, and dCMP. 33 A previous study shows increased AK4 protein level in hypoxia-treated cells and spinal cords of amyotrophic lateral sclerosis mice, suggesting the endogenous level of AK4 protein may elevate in response to various stress. 34 ITPK1 is a regulatory enzyme that plays a key role in intracellular inositol phosphate metabolism. 35 Higher phosphorylated forms of inositol in mammalian cells, IP6 in particular, are essential for life. Animal models show that reduced ITPK1 level can cause neural tube defects. 36 The role of these four proteins in aging-related cognitive decline not explained by known neuropathologies offers an opportunity to identify molecular drivers of cognition in old age that represent novel pathways. Causes of dementia are heterogeneous, and AD, cerebral vascular disease, Lewy bodies, and hippocampal sclerosis are traditionally thought to be the primary drivers for cognitive impairment and dementia. [37] [38] [39] However, recent evidence from clinical and postmortem data suggests that a majority of late-life cognitive decline is not attributed to these common neuropathologies. 40 Indeed, other pathological markers, TDP-43 and white matter changes for instance, also contribute to cognitive decline and dementia. 15, 41 Thus, proteins such as the four identified in this study may represent targets that are causally related to pathologies yet to be recognized or measured.
On the other hand, it is plausible that these proteins are involved in neurobiological substrates of resilience or reserve or in response to proteotoxic stress. For instance, the HSP families function as molecular chaperones to suppress stressed-induced protein unfolding. 42 As a result, change in HSP level has been observed in aging and neurodegenerative disorders such as AD and Parkinson's disease. 43 Previous studies also show that greater amount of multiple presynaptic proteins and their interactions reduce cognitive impairment and dementia risk, independent of AD pathology and infarcts, as does neuron density as well as cortical ENC1, UNC5C, and BDNF expression. 40, [44] [45] [46] [47] Considering that older persons with cognitive impairment or dementia most often have mixed neuropathologies, 48 targets for a specific pathology are clearly of high value. However, we recently showed that there are nearly 250 combinations of neuropathologies among just over 1,000 persons; no single combination was present in more than 10% of the sample, and nearly 100 people had a unique combination not present in any other person. 49 Thus, finding a therapeutic target that can drive cognition independent of common neuropathologies may be a more practical and cost-efficient approach to delaying the onset of Alzheimer's dementia. 50 Our network approach identified m109, that is, the module most proximal to cognitive decline. 3 Our two validation strategies have confirmed the importance of this set of genes and are beginning to dissect a series of correlated transcriptional programs involved in cognition. Our earlier work had shown that m109 is likely to be non-cell-autonomous given that its component genes are spread across several cell types, including astrocytes, microglia, and neurons: m109 may capture a set of intercellular signals that are important in advancing age. PLXNB1 appears to be an important driver of a minor component of m109, which influences amyloid pathology, whereas IGFBP5, HSPB2, AK4, and ITPK1 provide entry points to the more exciting nonamyloid components of cognitive decline that remain to be explored. These results illustrate the strength of the network approach in prioritizing key genes for further investigation as well as the essential role of multiple, complementary validation efforts to fully explore the role of prioritized genes that are unlikely to cleanly fit in a simple narrative. It also highlights the observation that, although the reductionist perspective of a molecular network is a powerful approach to initiate projects, it does not capture the full complexity of the pathobiology of the aging brain: It is a useful platform from which to launch investigations, but is just the start of a long road to understanding critical phenomena that may be targeted in future therapeutic development efforts. Given that proteins are the physical bases of neural networks and have served as the popular targets of most pharmaceutical interventions, our findings offer novel therapeutic targets for the prevention and treatment of cognitive decline and dementia. Nonetheless, the study has several limitations. First, lack of replicates within individual brains did not account for variability of protein expression attributed to spatial heterogeneity. Notably, this potential variability was effectively offset by the large sample size used in this study and the fact that variability would bias toward the null. Second, transcriptomic and proteomic data came from a single brain region, the DLPFC. Given that cognitive profiles may differ across brain regions, examination of other brain regions may help to identify additional proteins that are involved in cognitive impairment and dementia. Data collection from additional regions is currently underway. In addition, ROS and MAP are voluntary cohorts, and participants were older and highly educated. Thus, generalizability of these findings needs to be confirmed by samples from other longitudinal cohorts. The study also has many strengths. Findings are based on a large sample of autopsied individuals. The SRM proteomics technique, in combination with annual cognitive evaluations many years preceding death and comprehensive neuropathological assessments, provides unique, high-quality, multilevel data from same individuals to perform robust statistical modeling.
